IBEC ANNUAL REPORT 09 IBEC ANNUAL REPORT 09 “This Annual Report is the evidence of the work and effort to consolidate the position of IBEC as an international centre of reference” INTRODUCTION LETTER IBEC ANNUAL REPORT 09 3 It is with great satisfaction that I am presenting our 2009 Annual Report, a concise review of the work of the Institute over the last twelve months that bears witness to the consistent effort and solid achievements of all those who are working to further improve and develop this institution. This systematic review of our activities will, in time, serve as a record of the history of the IBEC, but we also want it to be a communicative tool that will inform those who read it about our scientific competence, our technological expertise, the talent we foster, and the excellent return we provide for the investment that finances our organisation. In terms of the research output in the last year, we have seen no increase in the number of scientific articles published, but there has been a marked increase in terms of impact of our publications, a good sign aligned with the objective to improve the quality/quantity balance. At the same time, we continue to attract talent from both our close surroundings and from abroad. In terms of competitive funding, the number of projects applied for and the funds received have both increased significantly, another good sign with respect to the quality/quantity balance we are looking for, since the responsibility for coordinating both National and European projects has also increased. In 2010, we will have the opportunity to increase and improve both the applicability and the transfer of our research. The consolidation of our Molecular and Cellular Neurobiotechnology research line and the incorporation of a new line of research, Control of Stem Cell Potency, represent significant progress in terms of IBEC’s interdisciplinary scientific ambitions. This expansion in the number of research groups has produced an increase in the number of researchers and the need for more space. In 2009, we have managed to bring all the teams together and to provide each research group with its own space. We can congratulate ourselves that all the research groups have now working space within the IBEC facilities. I would like to conclude by saying that our ambition to consolidate the position of IBEC as an international centre of reference in bioengineering and nanomedicine is alive and I hope that this Annual Report is the evidence of the work and effort that all of us, as IBEC members, are investing in achieving that goal. The relocation of the research groups in good laboratories, their proximity to one another, the interdisciplinary nature of our research teams, and the quality of our administration and support services will allow us to keep improving and making further progress not only towards the achievement of our own objectives but also towards the fulfillment of our social function of contributing to a better quality of life for everyone through advances in bioengineering and nanomedical research. Thank you! Josep A. Planell IBEC ANNUAL REPORT 09 5 HIGHLIGHTS 07 ORGANISATION 11 THE IBEC PRIVATE FOUNDATION 12 ORGANISATIONAL CHART 13 ORGANISATIONAL STRUCTURE 14 RESEARCH 17 RESEARCH LINES 18 RESEARCH PROJECTS 33 PUBLICATIONS 38 COLLABORATIONS WITH OTHER 42 RESEARCH CENTRES SCIENTIFIC EQUIPMENT AND 46 TECHNIQUES IBEC INITIATIVES 49 INSTITUTIONAL PROJECTS 50 AND ACTIVITIES STRATEGIC ALLIANCES 52 SEMINARS AND LECTURES 54 CONFERENCES AND SYMPOSIA 56 CONTENTS IBEC ANNUAL REPORT 09 7 HIGHLIGHTS HIGHLIGHTS IBEC Expands its Research Collaboration Agreements Program with a New Line of In the context of the Biopol’H project, IBEC and the Bellvitge Institute for Biomedical Research (IDIBELL) have signed a collabo- Stem Cell Investigation ration agreement covering the exchange of human resources, the organization of joint activities, shared use of facilities and equipment, Control of Stem Cell Potency is a research line recently initiated and participation in joint projects. The two institutes will collabora- under the leadership of Ángel Raya, a research professor at the te in the following areas: transplantation; bioengineering; implants; Catalan Institute for Research and Advanced Studies (ICREA). This tissue engineering and biocompatibility; new medical imaging tech- is within IBEC’s Cellular Biotechnology research programme. nologies; new technologies for molecular and genetic diagnosis; The focus of this new line of research is the regeneration of complex biomedical and bioelectronic engineering; and the neurosciences. structures, the biotechnology of cell reprogramming, and stem cell IBEC has signed a memorandum of understanding (MOU) with differentiation. The team uses the paradigm of heart (re)genera- the National Institute for Materials Science (NIMS) in Japan on the tion to address the basic question of how a discrete and defined “Design of Biomaterial Surfaces and Biosensors for Cell Function degree of developmental potency can be imposed on somatic cells, Manipulation and Analysis”. Under this agreement, NIMS and enabling them to regain the capacity to regenerate a functional IBEC will promote the exchange of researchers and information, structure or tissue. With this addition, the IBEC foundation now cooperate in research and development projects, and publish the has 15 research lines and is further consolidating the growth of its results of such research jointly. programmes of investigation. IBEC also signed a research agreement with the Interstaatliche Hochschule für Technick Buchs in Switzerland for cooperation 2nd IBEC Symposium on the “Development and fabrication of advanced polymeric 3D microfluidic structures”. The two research centres will contribute on Bioengineering and their knowledge and expertise to this project and collaborate on the Nanomedicine Held implementation of the results of the research in future applications. in Barcelona 2nd Annual Conference of the Some 300 scientists gathered at the World Trade Center in Barce- lona on 14th and 15th April for the 2nd IBEC Annual Symposium. Spanish Technology Platforms The participants presented details of their most recent research in on Biomedical Research, the areas of bioengineering and nanomedicine. Keynote speakers from Europe and the United States were internationally renowned Innovative Medicine, and scientists including Dr. Martin Bennink of the University of Twente in the Netherlands, Professor Alan Gelperin of the Monell Chemical Nanomedicine Senses Center in Philadelphia, Professor Frederick Grinnell of the The second annual conference of the Spanish Technology Pla- Southwestern Medical Center at the University of Texas, Profes- tform on Nanomedicine (Nanomed Spain) and the Spanish Tech- sor Michael Sheetz of Columbia University, Professor Keita Ito of nological Platform for Innovative Medicines took place in Madrid Eindhoven University in the Netherlands, Professor Nongjian Tao of on 27 and 28 January. This event is a meeting place for com- Arizona State University, and Angel Raya of the Center of Regene- panies and institutions working in these areas. The two Spanish rative Medicine in Barcelona. technology platforms working in the field of biomedicine presented their current projects. In particular, Nanomed Spain chose this conference to officially present its international innovation unit, Nanomed-UII. Another item of particular interest was the presen- tation describing the development of the roadmap for nanomedici- ne drawn up by the European Technology Platform on Nanomedi- cine, of which both IBEC and Nanomed Spain are members. Opening of NANOMED-UII, IBEC Hosts the 2nd China- the International Innovation Europe Symposium on Unit of the Spanish Platform Biomaterials in Regenerative on Nanomedicine Medicine Nanomed-UII was created in January 2009 as a result of a con- The 2nd China-Europe Symposium on Biomaterials in Regenerati- tract between the Spanish Platform on Nanomedicine (Nanomed ve Medicine took place in Barcelona from 16 to 20 November. This Spain) and the Centre for the Development of Industrial Tech- event brought together over 150 participants and the top spe- nology (CDTI). The mission of this international innovation unit cialists in biomaterials from China and Europe. The symposium, is to improve the participation of Spanish companies in projects organised by IBEC, was a joint initiative of the European Society financed by the European Union’s seventh framework programme, for Biomaterials and the Chinese Committee for Biomaterials. The in particular with respect to the application of nanotechnology goal was to showcase the latest research, to provide a forum for to healthcare. Nanomed-UII is now integrated into the existing the discussion of recent advances, to build relationships between structure of Nanomed Spain, a body established in 2005 which is European and Chinese researchers, and to promote collaboration coordinated by IBEC. in future research projects. The aim of this technology platform, which affiliates over 100 companies, hospitals and publically-funded research centres, in IBEC at Japan´s Nano Tech addition to representatives of official bodies, is to bring together the public and private sectors and develop joint strategies aimed at 2009 advancing the field of nanomedicine in Spain. IBEC attended the International Nanotechnology Exhibition and Conference, one of the world’s largest nanotechnology exhibitions, UK-Iberia Nanomedicine which took place in Tokyo from 18 to 20 February,